AN2 Therapeutics, Inc. (NASDAQ:ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today announced that four abstracts highlighting clinical and nonclinical data supporting the development of epetraborole, a novel boron-containing oral candidate for the treatment of polycythemia vera (PV), will be presented at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting, taking place September 9-12, 2026, at the George R. Brown Convention Center in Houston, Texas.